Hidradenitis suppurativa.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
12 03 2020
12 03 2020
Historique:
accepted:
23
01
2020
entrez:
14
3
2020
pubmed:
14
3
2020
medline:
3
2
2021
Statut:
epublish
Résumé
Hidradenitis suppurativa (HS; also designated as acne inversa) is a chronic inflammatory disorder, which affects the intertriginous skin and is associated with numerous systemic comorbidities. The estimated prevalence of HS is ~1% in most studied countries. Typically starting in early adulthood, cutaneous inflamed nodules, abscesses and pus-discharging tunnels develop in axillary, inguinal, gluteal and perianal body sites. The comorbidities of HS include metabolic and cardiovascular disorders, which contribute to reduced life expectancy. A genetic predisposition, smoking, obesity and hormonal factors are established aetiological factors for HS. Cutaneous changes seem to start around hair follicles and involve activation of cells of the innate and adaptive immune systems, with pivotal roles for pro-inflammatory cytokines such as tumour necrosis factor, IL-1β and IL-17. The unrestricted and chronic immune response eventually leads to severe pain, pus discharge, irreversible tissue destruction and scar development. HS has profound negative effects on patients' quality of life, which often culminate in social withdrawal, unemployment, depression and suicidal thoughts. The therapeutic options for HS comprise antibiotic treatment, neutralization of tumour necrosis factor and surgical intervention together with lifestyle modification. Nevertheless, there is an enormous need for awareness of HS, understanding of its pathogenesis and novel treatments.
Identifiants
pubmed: 32165620
doi: 10.1038/s41572-020-0149-1
pii: 10.1038/s41572-020-0149-1
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Inflammatory Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
18Commentaires et corrections
Type : CommentIn
Références
Saunte, D. M. L. & Jemec, G. B. E. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318, 2019–2032 (2017).
pubmed: 29183082
doi: 10.1001/jama.2017.16691
pmcid: 29183082
Ingram, J. R. et al. Population-based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br. J. Dermatol. 178, 917–924 (2018). This paper is a well-conducted registry study providing a realistic estimate of HS prevalence.
pubmed: 29094346
doi: 10.1111/bjd.16101
pmcid: 29094346
Theut Riis, P., Thorlacius, L., Knudsen List, E. & Jemec, G. B. E. A pilot study of unemployment in patients with hidradenitis suppurativa in Denmark. Br. J. Dermatol. 176, 1083–1085 (2017).
pubmed: 27480611
doi: 10.1111/bjd.14922
pmcid: 27480611
Matusiak, L., Bieniek, A. & Szepietowski, J. C. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J. Am. Acad. Dermatol. 62, 706–708 (2010).
pubmed: 20227585
doi: 10.1016/j.jaad.2009.09.021
pmcid: 20227585
Wolk, K. et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J. Immunol. 186, 1228–1239 (2011). This paper is the first investigation of the role of cytokines related to activated lymphocytes (for example, IL-17, IL-22, IL-26 and IFNγ) and myeloid cells (for example, IL-1β and IL-10), the elements of their pathways and their consequences in the skin of patients with HS.
pubmed: 21148041
doi: 10.4049/jimmunol.0903907
pmcid: 21148041
Sabat, R. et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 7, e31810 (2012). This paper is a comprehensive prospective case–control study that first reported the high prevalence of the metabolic syndrome in patients with HS, an observation most striking among young patients.
pubmed: 22359634
pmcid: 3281019
doi: 10.1371/journal.pone.0031810
Shlyankevich, J., Chen, A. J., Kim, G. E. & Kimball, A. B. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J. Am. Acad. Dermatol. 71, 1144–1150 (2014).
pubmed: 25440440
doi: 10.1016/j.jaad.2014.09.012
pmcid: 25440440
Schneider-Burrus, S. et al. High prevalence of back pain and axial spondyloarthropathy in patients with hidradenitis suppurativa. Dermatology 232, 606–612 (2016).
pubmed: 27649417
doi: 10.1159/000448838
pmcid: 27649417
Richette, P. et al. Hidradenitis suppurativa associated with spondyloarthritis — results from a multicenter national prospective study. J. Rheumatol. 41, 490–494 (2014).
pubmed: 24429166
doi: 10.3899/jrheum.130977
pmcid: 24429166
Deckers, I. E. et al. Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study. J. Am. Acad. Dermatol. 76, 49–53 (2017).
pubmed: 27793450
doi: 10.1016/j.jaad.2016.08.031
pmcid: 27793450
Egeberg, A. et al. Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa. J. Invest. Dermatol. 137, 1060–1064 (2017).
pubmed: 28089682
doi: 10.1016/j.jid.2016.11.040
pmcid: 28089682
Gonzalez-Lopez, M. A. et al. Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). J. Am. Acad. Dermatol. 75, 329–335 (2016).
pubmed: 27287248
doi: 10.1016/j.jaad.2016.03.025
pmcid: 27287248
Vazquez, B. G., Alikhan, A., Weaver, A. L., Wetter, D. A. & Davis, M. D. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J. Invest. Dermatol. 133, 97–103 (2013).
pubmed: 22931916
doi: 10.1038/jid.2012.255
pmcid: 22931916
Kurek, A., Johanne Peters, E. M., Sabat, R., Sterry, W. & Schneider-Burrus, S. Depression is a frequent co-morbidity in patients with acne inversa. J. Dtsch. Dermatol. Ges. 11, 743–750 (2013).
pubmed: 23565584
pmcid: 23565584
Jemec, G. B. & Kimball, A. B. Hidradenitis suppurativa: epidemiology and scope of the problem. J. Am. Acad. Dermatol. 73, S4–S7 (2015).
pubmed: 26470614
doi: 10.1016/j.jaad.2015.07.052
pmcid: 26470614
Ingvarsson, G. Regional variation of hidradenitis suppurativa in the Norwegian patient registry during a 5-year period may describe professional awareness of the disease, not changes in prevalence. Br. J. Dermatol. 176, 274–275 (2017).
pubmed: 27543427
doi: 10.1111/bjd.14990
pmcid: 27543427
Sung, S. & Kimball, A. B. Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J. Am. Acad. Dermatol. 69, 818–819 (2013).
pubmed: 24124816
doi: 10.1016/j.jaad.2013.06.043
pmcid: 24124816
Kurokawa, I., Hayashi, N. & Japan Acne Research, S. Questionnaire surveillance of hidradenitis suppurativa in Japan. J. Dermatol. 42, 747–749 (2015).
pubmed: 25898994
doi: 10.1111/1346-8138.12881
pmcid: 25898994
Lee, J. H., Kwon, H. S., Jung, H. M., Kim, G. M. & Bae, J. M. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J. Eur. Acad. Dermatol. Venereol. 32, 1784–1790 (2018).
pubmed: 29761904
doi: 10.1111/jdv.15071
pmcid: 29761904
Garg, A., Kirby, J. S., Lavian, J., Lin, G. & Strunk, A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 153, 760–764 (2017).
pubmed: 28492923
pmcid: 5710402
doi: 10.1001/jamadermatol.2017.0201
Jemec, G. B., Heidenheim, M. & Nielsen, N. H. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J. Am. Acad. Dermatol. 35, 191–194 (1996).
pubmed: 8708018
doi: 10.1016/S0190-9622(96)90321-7
pmcid: 8708018
Calao, M. et al. Hidradenitis suppurativa (HS) prevalence, demographics and management pathways in Australia: a population-based cross-sectional study. PLoS One 13, e0200683 (2018). This paper is a comprehensive study describing the prevalence of HS in the general population.
pubmed: 30040827
pmcid: 6057625
doi: 10.1371/journal.pone.0200683
Zouboulis, C. C. et al. Development and validation of the international hidradenitis suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity. Br. J. Dermatol. 177, 1401–1409 (2017). This paper describes the development of the IHS4, which has the potential to become the gold standard for the classification of patients with HS.
pubmed: 28636793
doi: 10.1111/bjd.15748
pmcid: 28636793
Deckers, I. E., van der Zee, H. H., Boer, J. & Prens, E. P. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J. Am. Acad. Dermatol. 72, 485–488 (2015).
pubmed: 25582541
doi: 10.1016/j.jaad.2014.11.017
pmcid: 25582541
Yang, J. H. et al. Demographic and clinical features of hidradenitis suppurativa in Korea. J. Dermatol. 45, 1389–1395 (2018).
pubmed: 30294846
doi: 10.1111/1346-8138.14656
pmcid: 30294846
Kromann, C. B. et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br. J. Dermatol. 171, 819–824 (2014).
pubmed: 24804604
doi: 10.1111/bjd.13090
pmcid: 24804604
Egeberg, A., Gislason, G. H. & Hansen, P. R. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol. 152, 429–434 (2016).
pubmed: 26885728
doi: 10.1001/jamadermatol.2015.6264
pmcid: 26885728
Ingram, J. R. The genetics of hidradenitis suppurativa. Dermatol. Clin. 34, 23–28 (2016).
pubmed: 26617354
doi: 10.1016/j.det.2015.07.002
pmcid: 26617354
von der Werth, J. M. & Williams, H. C. The natural history of hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 14, 389–392 (2000).
pubmed: 11305381
doi: 10.1046/j.1468-3083.2000.00087.x
pmcid: 11305381
Wang, B. et al. Gamma-secretase gene mutations in familial acne inversa. Science 330, 1065 (2010). This paper is the first study to demonstrate loss of function mutations in genes encoding γ-secretase, cumulatively found among members of Chinese families with severe HS.
pubmed: 20929727
doi: 10.1126/science.1196284
pmcid: 20929727
Haapasalo, A. & Kovacs, D. M. The many substrates of presenilin/gamma-secretase. J. Alzheimers Dis. 25, 3–28 (2011).
pubmed: 21335653
pmcid: 3281584
doi: 10.3233/JAD-2011-101065
Frew, J. W., Vekic, D. A., Woods, J. & Cains, G. D. A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa. Br. J. Dermatol. 177, 987–998 (2017).
pubmed: 28278367
doi: 10.1111/bjd.15441
pmcid: 28278367
Pan, Y. et al. γ-Secretase functions through Notch signaling to maintain skin appendages but is not required for their patterning or initial morphogenesis. Dev. Cell 7, 731–743 (2004).
pubmed: 15525534
doi: 10.1016/j.devcel.2004.09.014
pmcid: 15525534
O’Sullivan Coyne, G., Woodring, T. S., Lee, C. R., Chen, A. P. & Kong, H. H. Hidradenitis suppurativa-like lesions associated with pharmacologic inhibition of gamma-secretase. J. Invest. Dermatol. 138, 979–981 (2018).
pubmed: 29138057
doi: 10.1016/j.jid.2017.09.051
pmcid: 29138057
Aubin-Houzelstein, G. Notch signaling and the developing hair follicle. Adv. Exp. Med. Biol. 727, 142–160 (2012).
pubmed: 22399345
doi: 10.1007/978-1-4614-0899-4_11
pmcid: 22399345
Asano, N., Watanabe, T., Kitani, A., Fuss, I. J. & Strober, W. Notch1 signaling and regulatory T cell function. J. Immunol. 180, 2796–2804 (2008).
pubmed: 18292500
doi: 10.4049/jimmunol.180.5.2796
pmcid: 18292500
Ali, N. et al. Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell 169, 1119–1129 (2017).
pubmed: 28552347
pmcid: 5504703
doi: 10.1016/j.cell.2017.05.002
Lowell, S., Jones, P., Le Roux, I., Dunne, J. & Watt, F. M. Stimulation of human epidermal differentiation by delta-notch signalling at the boundaries of stem-cell clusters. Curr. Biol. 10, 491–500 (2000).
pubmed: 10801437
doi: 10.1016/S0960-9822(00)00451-6
pmcid: 10801437
Alam, M. S. et al. Notch signaling drives IL-22 secretion in CD4+ T cells by stimulating the aryl hydrocarbon receptor. Proc. Natl Acad. Sci. USA 107, 5943–5948 (2010).
pubmed: 20231432
doi: 10.1073/pnas.0911755107
pmcid: 20231432
Pang, B. et al. Elevated Notch1 enhances interleukin-22 production by CD4
pubmed: 30473538
pmcid: 6294615
doi: 10.1042/BSR20181922
Wolk, K. et al. IL-22 increases the innate immunity of tissues. Immunity 21, 241–254 (2004).
pubmed: 15308104
doi: 10.1016/j.immuni.2004.07.007
pmcid: 15308104
Pink, A. E. et al. Mutations in the gamma-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J. Invest. Dermatol. 132, 2459–2461 (2012).
pubmed: 22622421
doi: 10.1038/jid.2012.162
pmcid: 22622421
Liu, M. et al. Genetic analysis of NCSTN for potential association with hidradenitis suppurativa in familial and nonfamilial patients. Br. J. Dermatol. 175, 414–416 (2016).
pubmed: 26879264
doi: 10.1111/bjd.14482
pmcid: 26879264
Ingram, J. R., Wood, M., John, B., Butler, R. & Anstey, A. V. Absence of pathogenic gamma-secretase mutations in a South Wales cohort of familial and sporadic hidradenitis suppurativa (acne inversa). Br. J. Dermatol. 168, 874–876 (2013).
pubmed: 23013355
doi: 10.1111/bjd.12048
pmcid: 23013355
Giatrakos, S. et al. Haplotypes of IL-12Rbeta1 impact on the clinical phenotype of hidradenitis suppurativa. Cytokine 62, 297–301 (2013).
pubmed: 23557799
doi: 10.1016/j.cyto.2013.03.008
pmcid: 23557799
Vural, S. et al. Association of pyrin mutations and autoinflammation with complex phenotype hidradenitis suppurativa: a case-control study. Br. J. Dermatol. 180, 1459–1467 (2019).
pubmed: 30488432
doi: 10.1111/bjd.17466
pmcid: 30488432
Revuz, J. E. et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J. Am. Acad. Dermatol. 59, 596–601 (2008).
pubmed: 18674845
doi: 10.1016/j.jaad.2008.06.020
pmcid: 18674845
Konig, A., Lehmann, C., Rompel, R. & Happle, R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 198, 261–264 (1999).
pubmed: 10393449
doi: 10.1159/000018126
pmcid: 10393449
Hana, A. et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci. 80, 2214–2220 (2007).
pubmed: 17363005
doi: 10.1016/j.lfs.2007.02.007
pmcid: 17363005
Radek, K. A. et al. Neuroendocrine nicotinic receptor activation increases susceptibility to bacterial infections by suppressing antimicrobial peptide production. Cell Host Microbe 7, 277–289 (2010).
pubmed: 20413096
pmcid: 2916230
doi: 10.1016/j.chom.2010.03.009
Wu, Y. et al. Nicotine enhances Staphylococcus epidermidis biofilm formation by altering the bacterial autolysis, extracellular DNA releasing, and polysaccharide intercellular adhesin production. Front. Microbiol. 9, 2575 (2018).
pubmed: 30420846
pmcid: 6215848
doi: 10.3389/fmicb.2018.02575
Wittebole, X. et al. Nicotine exposure alters in vivo human responses to endotoxin. Clin. Exp. Immunol. 147, 28–34 (2007).
pubmed: 17177960
pmcid: 1810444
Boer, J. Should hidradenitis suppurativa be included in dermatoses showing Koebnerization? Is it friction or fiction? Dermatology 233, 47–52 (2017).
pubmed: 28505620
doi: 10.1159/000472252
pmcid: 28505620
Alikhan, A., Lynch, P. J. & Eisen, D. B. Hidradenitis suppurativa: a comprehensive review. J. Am. Acad. Dermatol. 60, 539–561; quiz 562–563 (2009).
pubmed: 19293006
doi: 10.1016/j.jaad.2008.11.911
pmcid: 19293006
Riis, P. T., Ring, H. C., Themstrup, L. & Jemec, G. B. The role of androgens and estrogens in hidradenitis suppurativa — a systematic review. Acta Dermatovenerol. Croat. 24, 239–249 (2016).
pubmed: 28128074
pmcid: 28128074
Karagiannidis, I., Nikolakis, G., Sabat, R. & Zouboulis, C. C. Hidradenitis suppurativa/acne inversa: an endocrine skin disorder? Rev. Endocr. Metab. Disord. 17, 335–341 (2016).
pubmed: 27294593
doi: 10.1007/s11154-016-9366-z
pmcid: 27294593
Gauntner, T. D. Hormonal, stem cell and Notch signalling as possible mechanisms of disease in hidradenitis suppurativa: a systems-level transcriptomic analysis. Br. J. Dermatol. 180, 203–204 (2019).
pubmed: 30117141
doi: 10.1111/bjd.17093
pmcid: 30117141
Jenei, A. et al. Apocrine gland-rich skin has a non-inflammatory IL-17-related immune milieu, that turns to inflammatory IL-17-mediated disease in hidradenitis suppurativa. J. Invest. Dermatol. 139, 964–968 (2019).
pubmed: 30391261
doi: 10.1016/j.jid.2018.10.020
pmcid: 30391261
Kamp, S. et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br. J. Dermatol. 164, 1017–1022 (2011).
pubmed: 21250966
doi: 10.1111/j.1365-2133.2011.10224.x
pmcid: 21250966
Naik, H. B. et al. Are bacteria infectious pathogens in hidradenitis suppurativa? Debate at the symposium for hidradenitis suppurativa advances meeting, November 2017. J. Invest. Dermatol. 139, 13–16 (2019).
pubmed: 30414909
doi: 10.1016/j.jid.2018.09.036
pmcid: 30414909
Guet-Revillet, H. et al. The microbiological landscape of anaerobic infections in hidradenitis suppurativa: a prospective metagenomic study. Clin. Infect. Dis. 65, 282–291 (2017). This paper investigates intracutaneous bacterial colonization in patients with HS and shows the enrichment of specific Gram-negative anaerobic species in chronic HS lesions.
pubmed: 28379372
doi: 10.1093/cid/cix285
pmcid: 28379372
Nikolakis, G. et al. Bacteriology of hidradenitis suppurativa/acne inversa: a review. J. Am. Acad. Dermatol. 73, S12–S18 (2015).
pubmed: 26470608
doi: 10.1016/j.jaad.2015.07.041
pmcid: 26470608
Ring, H. C. et al. The bacteriology of hidradenitis suppurativa: a systematic review. Exp. Dermatol. 24, 727–731 (2015).
pubmed: 26119625
doi: 10.1111/exd.12793
pmcid: 26119625
Kathju, S., Lasko, L. A. & Stoodley, P. Considering hidradenitis suppurativa as a bacterial biofilm disease. FEMS Immunol. Med. Microbiol. 65, 385–389 (2012).
pubmed: 22353357
doi: 10.1111/j.1574-695X.2012.00946.x
pmcid: 22353357
Ring, H. C. et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br. J. Dermatol. 176, 993–1000 (2017).
pubmed: 27564400
doi: 10.1111/bjd.15007
pmcid: 27564400
Ring, H. C. et al. Normal skin microbiota is altered in pre-clinical hidradenitis suppurativa. Acta Derm. Venereol. 97, 208–213 (2017).
pubmed: 27377144
doi: 10.2340/00015555-2503
pmcid: 27377144
De Vita, V. & Fabbrocini, G. Mechanical stress as a cause of hidradenitis suppurativa: a lesson from a patient with a monster hernia. Acta Dermatovenerol. Croat. 26, 260–261 (2018).
pubmed: 30390729
pmcid: 30390729
Yu, C. C. & Cook, M. G. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br. J. Dermatol. 122, 763–769 (1990). This paper describes an early histopathological study that suggests that HS develops upon dilatation and rupture of hair follicles.
pubmed: 2369556
doi: 10.1111/j.1365-2133.1990.tb06264.x
pmcid: 2369556
Attanoos, R. L., Appleton, M. A. & Douglas-Jones, A. G. The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br. J. Dermatol. 133, 254–258 (1995).
pubmed: 7547393
doi: 10.1111/j.1365-2133.1995.tb02624.x
pmcid: 7547393
Boer, J. & Weltevreden, E. F. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br. J. Dermatol. 135, 721–725 (1996).
pubmed: 8977671
doi: 10.1111/j.1365-2133.1996.tb03880.x
pmcid: 8977671
Jemec, G. B. & Hansen, U. Histology of hidradenitis suppurativa. J. Am. Acad. Dermatol. 34, 994–999 (1996).
pubmed: 8647993
doi: 10.1016/S0190-9622(96)90277-7
pmcid: 8647993
von Laffert, M. et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp. Dermatol. 19, 533–537 (2010).
doi: 10.1111/j.1600-0625.2009.00915.x
van der Zee, H. H. et al. Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br. J. Dermatol. 164, 1292–1298 (2011).
pubmed: 21332464
doi: 10.1111/j.1365-2133.2011.10254.x
pmcid: 21332464
Hunger, R. E., Surovy, A. M., Hassan, A. S., Braathen, L. R. & Yawalkar, N. Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. Br. J. Dermatol. 158, 691–697 (2008).
pubmed: 18241264
doi: 10.1111/j.1365-2133.2007.08425.x
pmcid: 18241264
Witte-Handel, E. et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J. Invest. Dermatol. 139, 1294–1305 (2019). This paper elucidates the role of IL-1β in cutaneous purulence and tissue destruction by transcriptome analyses, stimulation studies with skin-derived cells and ex vivo cytokine neutralization of HS skin.
pubmed: 30528824
doi: 10.1016/j.jid.2018.11.018
pmcid: 30528824
Kelly, G. et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br. J. Dermatol. 173, 1431–1439 (2015).
pubmed: 26282467
doi: 10.1111/bjd.14075
pmcid: 26282467
Manfredini, M. et al. The P2X7 receptor is overexpressed in the lesional skin of subjects affected by hidradenitis suppurativa: a preliminary study. Dermatology https://doi.org/10.1159/000502026 (2019).
doi: 10.1159/000502026
pubmed: 31454821
pmcid: 31454821
Dinarello, C. A., Simon, A. & van der Meer, J. W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug. Discov. 11, 633–652 (2012).
pubmed: 22850787
pmcid: 3644509
doi: 10.1038/nrd3800
Sedger, L. M. & McDermott, M. F. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants — past, present and future. Cytokine Growth Factor. Rev. 25, 453–472 (2014).
pubmed: 25169849
doi: 10.1016/j.cytogfr.2014.07.016
pmcid: 25169849
Wolk, K. et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J. Mol. Med. 87, 523–536 (2009).
pubmed: 19330474
doi: 10.1007/s00109-009-0457-0
pmcid: 19330474
Kimball, A. B. et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N. Engl. J. Med. 375, 422–434 (2016). This paper describes the first large RCT in HS.
pubmed: 27518661
doi: 10.1056/NEJMoa1504370
pmcid: 27518661
van der Zee, H. H. et al. Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br. J. Dermatol. 166, 98–106 (2012). This paper is the first study presenting immunostaining data demonstrating that keratin fibres act as foreign body material in the skin of patients with HS.
pubmed: 21929531
doi: 10.1111/j.1365-2133.2011.10643.x
pmcid: 21929531
List, E. K., Pascual, J. C., Zarchi, K., Nurnberg, B. M. & Jemec, G. B. E. Mast cells in hidradenitis suppurativa: a clinicopathological study. Arch. Dermatol. Res. 311, 331–335 (2019).
pubmed: 30877368
doi: 10.1007/s00403-019-01910-3
pmcid: 30877368
Platzer, C. et al. Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells. Eur. J. Immunol. 29, 3098–3104 (1999).
pubmed: 10540320
doi: 10.1002/(SICI)1521-4141(199910)29:10<3098::AID-IMMU3098>3.0.CO;2-H
pmcid: 10540320
Platzer, C., Meisel, C., Vogt, K., Platzer, M. & Volk, H. D. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int. Immunol. 7, 517–523 (1995).
pubmed: 7547677
doi: 10.1093/intimm/7.4.517
pmcid: 7547677
Sabat, R. et al. Biology of interleukin-10. Cytokine Growth Factor. Rev. 21, 331–344 (2010).
pubmed: 21115385
doi: 10.1016/j.cytogfr.2010.09.002
pmcid: 21115385
Fiorentino, D. F. et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146, 3444–3451 (1991).
pubmed: 1827484
pmcid: 1827484
Wolk, K., Docke, W., von Baehr, V., Volk, H. & Sabat, R. Comparison of monocyte functions after LPS- or IL-10-induced reorientation: importance in clinical immunoparalysis. Pathobiology 67, 253–256 (1999).
pubmed: 10725796
doi: 10.1159/000028104
pmcid: 10725796
Hotz, C. et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J. Invest. Dermatol. 136, 1768–1780 (2016).
pubmed: 27206704
doi: 10.1016/j.jid.2016.04.036
pmcid: 27206704
Moran, B. et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy. J. Invest. Dermatol. 137, 2389–2395 (2017). This paper uses multi-colour flow cytometry to investigate the cytokine production capacity of T cells derived from lesional and perilesional skin compared with unaffected HS skin. The results show the enrichment of CD4
pubmed: 28652108
doi: 10.1016/j.jid.2017.05.033
pmcid: 28652108
Sabat, R., Wolk, K., Loyal, L., Docke, W. D. & Ghoreschi, K. T cell pathology in skin inflammation. Semin. Immunopathol. 41, 359–377 (2019).
pubmed: 31028434
pmcid: 6505509
doi: 10.1007/s00281-019-00742-7
Schroder, K., Hertzog, P. J., Ravasi, T. & Hume, D. A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75, 163–189 (2004).
pubmed: 14525967
doi: 10.1189/jlb.0603252
pmcid: 14525967
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J. & Struyf, S. CXCR3 ligands in disease and therapy. Cytokine Growth Factor. Rev. 26, 311–327 (2015).
pubmed: 25498524
doi: 10.1016/j.cytogfr.2014.11.009
pmcid: 25498524
Vossen, A. et al. Novel cytokine and chemokine markers of hidradenitis suppurativa reflect chronic inflammation and itch. Allergy 74, 631–634 (2019).
pubmed: 30421795
pmcid: 30421795
Kao, C. Y. et al. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J. Immunol. 173, 3482–3491 (2004).
pubmed: 15322213
doi: 10.4049/jimmunol.173.5.3482
pmcid: 15322213
Albanesi, C., Cavani, A. & Girolomoni, G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J. Immunol. 162, 494–502 (1999).
pubmed: 9886425
pmcid: 9886425
Fossiez, F. et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183, 2593–2603 (1996).
pubmed: 8676080
doi: 10.1084/jem.183.6.2593
pmcid: 8676080
Wolk, K. et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur. J. Immunol. 39, 3570–3581 (2009).
pubmed: 19830738
doi: 10.1002/eji.200939687
pmcid: 19830738
Witte, E. et al. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J. Invest. Dermatol. 134, 2757–2767 (2014).
pubmed: 25046339
doi: 10.1038/jid.2014.308
pmcid: 25046339
Liang, S. C. et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203, 2271–2279 (2006).
pubmed: 16982811
pmcid: 2118116
doi: 10.1084/jem.20061308
Shen, F., Ruddy, M. J., Plamondon, P. & Gaffen, S. L. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-alpha-induced genes in bone cells. J. Leukoc. Biol. 77, 388–399 (2005).
pubmed: 15591425
doi: 10.1189/jlb.0904490
pmcid: 15591425
Weiss, B. et al. Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart. Genes Immun. 5, 330–336 (2004).
pubmed: 15201862
doi: 10.1038/sj.gene.6364104
pmcid: 15201862
Sabat, R., Ouyang, W. & Wolk, K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat. Rev. Drug. Discov. 13, 21–38 (2014).
pubmed: 24378801
doi: 10.1038/nrd4176
pmcid: 24378801
Mozeika, E., Pilmane, M., Nurnberg, B. M. & Jemec, G. B. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa. Acta Derm. Venereol. 93, 301–304 (2013).
pubmed: 23096596
doi: 10.2340/00015555-1492
pmcid: 23096596
Radaeva, S., Sun, R., Pan, H. N., Hong, F. & Gao, B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39, 1332–1342 (2004).
pubmed: 15122762
doi: 10.1002/hep.20184
pmcid: 15122762
Gimblet, C. et al. IL-22 protects against tissue damage during cutaneous leishmaniasis. PLoS One 10, e0134698 (2015).
pubmed: 26285207
pmcid: 4540492
doi: 10.1371/journal.pone.0134698
Chestovich, P. J. et al. Interleukin-22: implications for liver ischemia-reperfusion injury. Transplantation 93, 485–492 (2012).
pubmed: 22262131
pmcid: 3402175
doi: 10.1097/TP.0b013e3182449136
Sabat, R. & Wolk, K. Deciphering the role of interleukin-22 in metabolic alterations. Cell Biosci. 5, 68 (2015).
pubmed: 26674616
pmcid: 4678716
doi: 10.1186/s13578-015-0060-8
Wang, X. et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 514, 237–241 (2014).
pubmed: 25119041
doi: 10.1038/nature13564
pmcid: 25119041
Danby, F. W., Jemec, G. B., Marsch, W. & von Laffert, M. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br. J. Dermatol. 168, 1034–1039 (2013).
pubmed: 23320858
doi: 10.1111/bjd.12233
pmcid: 23320858
Greb, J. E. et al. Psoriasis. Nat. Rev. Dis. Prim. 2, 16082 (2016).
pubmed: 27883001
doi: 10.1038/nrdp.2016.82
pmcid: 27883001
Thomi, R. et al. Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa. Br. J. Dermatol. 177, 1358–1366 (2017).
pubmed: 28301691
doi: 10.1111/bjd.15458
pmcid: 28301691
Thomi, R., Kakeda, M., Yawalkar, N., Schlapbach, C. & Hunger, R. E. Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 31, 2091–2096 (2017).
pubmed: 28602023
doi: 10.1111/jdv.14389
pmcid: 28602023
Di Caprio, R. et al. IL-36 cytokines are increased in acne and hidradenitis suppurativa. Arch. Dermatol. Res. 309, 673–678 (2017).
pubmed: 28852851
doi: 10.1007/s00403-017-1769-5
pmcid: 28852851
Hessam, S. et al. Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop. Br. J. Dermatol. 178, 761–767 (2018).
pubmed: 28975626
doi: 10.1111/bjd.16019
pmcid: 28975626
Foster, A. M. et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J. Immunol. 192, 6053–6061 (2014).
pubmed: 24829417
pmcid: 4048788
doi: 10.4049/jimmunol.1301481
Winkle, S. M., Throop, A. L. & Herbst-Kralovetz, M. M. IL-36gamma augments host defense and immune responses in human female reproductive tract epithelial cells. Front. Microbiol. 7, 955 (2016).
pubmed: 27379082
pmcid: 4911402
doi: 10.3389/fmicb.2016.00955
Wolk, K. et al. Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. Br. J. Dermatol. 177, 1385–1393 (2017).
pubmed: 28256718
doi: 10.1111/bjd.15424
pmcid: 28256718
Abella, V. et al. The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases. Biomarkers 20, 565–571 (2015).
pubmed: 26671823
pmcid: 4819811
doi: 10.3109/1354750X.2015.1123354
Chakraborty, S., Kaur, S., Guha, S. & Batra, S. K. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta 1826, 129–169 (2012).
pubmed: 22513004
pmcid: 3362670
Thomi, R. et al. Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1/Th17 immune response. Exp. Dermatol. 27, 172–177 (2018).
pubmed: 29222824
doi: 10.1111/exd.13482
pmcid: 29222824
von Laffert, M., Stadie, V., Wohlrab, J. & Marsch, W. C. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br. J. Dermatol. 164, 367–371 (2011).
doi: 10.1111/j.1365-2133.2010.10034.x
Jimenez-Gallo, D. et al. The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm. 2017, 2450401 (2017).
pubmed: 28769536
pmcid: 5523401
doi: 10.1155/2017/2450401
Wolk, K. & Sabat, R. Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev. Endocr. Metab. Disord. 17, 305–317 (2016).
pubmed: 27554109
doi: 10.1007/s11154-016-9381-0
pmcid: 27554109
Malara, A. et al. Adipokines are dysregulated in patients with hidradenitis suppurativa. Br. J. Dermatol. 178, 792–793 (2018).
pubmed: 28834543
doi: 10.1111/bjd.15904
pmcid: 28834543
Girouard, S. D., Falk, R. H., Rennke, H. G. & Merola, J. F. Hidradenitis suppurativa resulting in systemic amyloid A amyloidosis: a case report and review of the literature. Dermatol. Online J. 18, 2 (2012).
pubmed: 22301039
pmcid: 22301039
Schandorff, K. D., Miller, I. M., Krustrup, D., Jemec, G. B. & Marckmann, P. Renal amyloid A amyloidosis as a complication of hidradenitis suppurativa. Clin. Nephrol. 86, 51–54 (2016).
pubmed: 27340120
doi: 10.5414/CN108787
pmcid: 27340120
Damen, M., Popa, C. D., Netea, M. G., Dinarello, C. A. & Joosten, L. A. B. Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases. Atherosclerosis 264, 83–91 (2017).
pubmed: 28716457
doi: 10.1016/j.atherosclerosis.2017.07.005
pmcid: 28716457
Tsaousi, A. et al. MMP8 is increased in lesions and blood of acne inversa patients: a potential link to skin destruction and metabolic alterations. Mediators Inflamm. 2016, 4097574 (2016).
pubmed: 27843200
pmcid: 5097814
doi: 10.1155/2016/4097574
Matusiak, L., Bieniek, A. & Szepietowski, J. C. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm. Venereol. 89, 601–603 (2009).
pubmed: 19997690
doi: 10.2340/00015555-0749
pmcid: 19997690
Matusiak, L., Szczech, J., Bieniek, A., Nowicka-Suszko, D. & Szepietowski, J. C. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J. Am. Acad. Dermatol. 76, 670–675 (2017).
pubmed: 28041632
doi: 10.1016/j.jaad.2016.10.042
pmcid: 28041632
Armaka, M. et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J. Exp. Med. 205, 331–337 (2008).
pubmed: 18250193
pmcid: 2271010
doi: 10.1084/jem.20070906
Uluckan, O. et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci. Transl. Med. 8, 330ra337 (2016).
doi: 10.1126/scitranslmed.aad8996
Freysz, M., Jemec, G. B. & Lipsker, D. A systematic review of terms used to describe hidradenitis suppurativa. Br. J. Dermatol. 173, 1298–1300 (2015).
pubmed: 26054001
doi: 10.1111/bjd.13940
pmcid: 26054001
Revuz, J. Hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 23, 985–998 (2009).
pubmed: 19682181
doi: 10.1111/j.1468-3083.2009.03356.x
pmcid: 19682181
Schrader, A. M., Deckers, I. E., van der Zee, H. H., Boer, J. & Prens, E. P. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J. Am. Acad. Dermatol. 71, 460–467 (2014). This paper reports on risk factors in a large representative cohort of patients with HS.
pubmed: 24880664
doi: 10.1016/j.jaad.2014.04.001
pmcid: 24880664
Saunte, D. M. et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br. J. Dermatol. 173, 1546–1549 (2015).
pubmed: 26198191
doi: 10.1111/bjd.14038
pmcid: 26198191
Wortsman, X., Castro, A. & Figueroa, A. Color Doppler ultrasound assessment of morphology and types of fistulous tracts in hidradenitis suppurativa (HS). J. Am. Acad. Dermatol. 75, 760–767 (2016).
pubmed: 27498279
doi: 10.1016/j.jaad.2016.05.009
pmcid: 27498279
Wortsman, X. et al. Ultrasound in-depth characterization and staging of hidradenitis suppurativa. Dermatol. Surg. 39, 1835–1842 (2013).
pubmed: 24118433
doi: 10.1111/dsu.12329
pmcid: 24118433
Virgilio, E., Bocchetti, T. & Balducci, G. Utility of MRI in the diagnosis and post-treatment evaluation of anogenital hidradenitis suppurativa. Dermatol. Surg. 41, 865–866 (2015).
pubmed: 26035049
doi: 10.1097/DSS.0000000000000379
pmcid: 26035049
Hurley, H. in Dermatologic Surgery: Principles and Practice (eds Roenigk, R. K., Roenigk, H. H. Jr). 729–739 (CRC Press, 1989).
Sartorius, K., Emtestam, L., Jemec, G. B. & Lapins, J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br. J. Dermatol. 161, 831–839 (2009).
pubmed: 19438453
doi: 10.1111/j.1365-2133.2009.09198.x
pmcid: 19438453
Kimball, A. B. et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann. Intern. Med. 157, 846–855 (2012).
pubmed: 23247938
doi: 10.7326/0003-4819-157-12-201212180-00004
pmcid: 23247938
Hessam, S. et al. A novel severity assessment scoring system for hidradenitis suppurativa. JAMA Dermatol. 154, 330–335 (2018).
pubmed: 29417136
pmcid: 5885841
doi: 10.1001/jamadermatol.2017.5890
Kokolakis, G. & Sabat, R. Distinguishing mild, moderate, and severe hidradenitis suppurativa. JAMA Dermatol. 154, 971–972 (2018).
pubmed: 29926079
doi: 10.1001/jamadermatol.2018.1599
pmcid: 29926079
Horvath, B. et al. Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert Group. Acta Derm. Venereol. 97, 412–413 (2017).
pubmed: 27535129
doi: 10.2340/00015555-2513
pmcid: 27535129
Chernyshov, P. V. The evolution of quality of life assessment and use in dermatology. Dermatology 235, 167–174 (2019).
pubmed: 30928986
doi: 10.1159/000496923
pmcid: 30928986
Ferreira-Valente, M. A., Pais-Ribeiro, J. L. & Jensen, M. P. Validity of four pain intensity rating scales. Pain 152, 2399–2404 (2011).
pubmed: 21856077
doi: 10.1016/j.pain.2011.07.005
pmcid: 21856077
Kimball, A. B. et al. Psychometric properties of the itch numeric rating scale in patients with moderate-to-severe plaque psoriasis. Br. J. Dermatol. 175, 157–162 (2016).
pubmed: 26852717
doi: 10.1111/bjd.14464
pmcid: 26852717
Pedersen, C. B. et al. Reliability and validity of the psoriasis itch visual analog scale in psoriasis vulgaris. J. Dermatol. Treat. 28, 213–220 (2017).
doi: 10.1080/09546634.2016.1215405
Spinhoven, P. et al. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol. Med. 27, 363–370 (1997).
pubmed: 9089829
doi: 10.1017/S0033291796004382
pmcid: 9089829
Yao, Y., Jorgensen, A. R. & Thomsen, S. F. Work productivity and activity impairment in patients with hidradenitis suppurativa: a cross-sectional study. Int. J. Dermatol. 59, 333–340 (2019).
pubmed: 31736064
doi: 10.1111/ijd.14706
pmcid: 31736064
Wieland, C. W. et al. Myeloid marker S100A8/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity? Br. J. Dermatol. 168, 1252–1258 (2013).
pubmed: 23320892
doi: 10.1111/bjd.12234
pmcid: 23320892
Matusiak, L., Salomon, J., Nowicka-Suszko, D., Bieniek, A. & Szepietowski, J. C. Chitinase-3-like protein 1 (YKL-40): novel biomarker of hidradenitis suppurativa disease activity? Acta Derm. Venereol. 95, 736–737 (2015).
pubmed: 25655759
doi: 10.2340/00015555-2061
pmcid: 25655759
Grant, A., Gonzalez, T., Montgomery, M. O., Cardenas, V. & Kerdel, F. A. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J. Am. Acad. Dermatol. 62, 205–217 (2010).
pubmed: 20115947
doi: 10.1016/j.jaad.2009.06.050
pmcid: 20115947
Gold, D. A., Reeder, V. J., Mahan, M. G. & Hamzavi, I. H. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J. Am. Acad. Dermatol. 70, 699–703 (2014).
pubmed: 24433875
doi: 10.1016/j.jaad.2013.11.014
pmcid: 24433875
Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2018).
pubmed: 29050646
doi: 10.1016/S0140-6736(17)32448-0
pmcid: 29050646
van der Zee, H. H., de Winter, K., van der Woude, C. J. & Prens, E. P. The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. Br. J. Dermatol. 171, 673–675 (2014).
pubmed: 24673289
doi: 10.1111/bjd.13002
pmcid: 24673289
Deckers, I. E., van der Zee, H. H. & Prens, E. P. Severe fatigue based on anaemia in patients with hidradenitis suppurativa: report of two cases and a review of the literature. J. Eur. Acad. Dermatol. Venereol. 30, 174–175 (2016).
pubmed: 25185839
doi: 10.1111/jdv.12680
pmcid: 25185839
Fraenkel, P. G. Anemia of inflammation: a review. Med. Clin. North. Am. 101, 285–296 (2017).
pubmed: 28189171
doi: 10.1016/j.mcna.2016.09.005
pmcid: 28189171
Cugno, M., Borghi, A. & Marzano, A. V. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment. Am. J. Clin. Dermatol. 18, 555–562 (2017).
pubmed: 28236224
doi: 10.1007/s40257-017-0265-1
pmcid: 28236224
Vanlaerhoven, A. et al. Hurley III hidradenitis suppurativa has an aggressive disease course. Dermatology 234, 232–233 (2018).
pubmed: 30149383
pmcid: 6390447
doi: 10.1159/000491547
Kromann, C. B., Ibler, K. S., Kristiansen, V. B. & Jemec, G. B. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm. Venereol. 94, 553–557 (2014).
pubmed: 24577555
doi: 10.2340/00015555-1800
Micieli, R. & Alavi, A. Lymphedema in patients with hidradenitis suppurativa: a systematic review of published literature. Int. J. Dermatol. 57, 1471–1480 (2018).
pubmed: 30105858
doi: 10.1111/ijd.14173
pmcid: 30105858
Russ, E. & Castillo, M. Lumbosacral epidural abscess due to hidradenitis suppurativa. AJR Am. J. Roentgenol. 178, 770–771 (2002).
pubmed: 11856724
doi: 10.2214/ajr.178.3.1780770
pmcid: 11856724
Chapman, S., Delgadillo, D. III, Barber, C. & Khachemoune, A. Cutaneous squamous cell carcinoma complicating hidradenitis suppurativa: a review of the prevalence, pathogenesis, and treatment of this dreaded complication. Acta Dermatovenerol. Alp. Pannonica Adriat. 27, 25–28 (2018).
pubmed: 29589641
pmcid: 29589641
Tannenbaum, R., Strunk, A. & Garg, A. Association between hidradenitis suppurativa and lymphoma. JAMA Dermatol. 155, 624–625 (2019).
pubmed: 30698627
pmcid: 6506877
doi: 10.1001/jamadermatol.2018.5230
Wortsman, X. Imaging of hidradenitis suppurativa. Dermatol. Clin. 34, 59–68 (2016).
pubmed: 26617359
doi: 10.1016/j.det.2015.08.003
pmcid: 26617359
Sivanand, A., Gulliver, W. P., Josan, C. K., Alhusayen, R. & Fleming, P. J. Weight loss and dietary interventions for hidradenitis suppurativa: a systematic review. J. Cutan. Med. Surg. 24, 64–72 (2019).
pubmed: 31502868
doi: 10.1177/1203475419874412
pmcid: 31502868
Loh, T. Y., Hendricks, A. J., Hsiao, J. L. & Shi, V. Y. Undergarment and fabric selection in the management of hidradenitis suppurativa. Dermatology https://doi.org/10.1159/000501611 (2019).
doi: 10.1159/000501611
pubmed: 31466052
pmcid: 31466052
Hunger, R. E. et al. Swiss practice recommendations for the management of hidradenitis suppurativa/acne inversa. Dermatology 233, 113–119 (2017).
pubmed: 28683447
doi: 10.1159/000477459
pmcid: 28683447
Megna, M. et al. Hidradenitis suppurativa: guidelines of the Italian society of dermatology and venereology (SIDeMaST) for the use of anti-TNF-α agents. G. Ital. Dermatol. Venereol. 150, 731–739 (2015).
pubmed: 26513043
pmcid: 26513043
Zouboulis, C. C. et al. S1 guideline for the treatment of hidradenitis suppurativa/acne inversa * (number ICD-10 L73.2) [German]. J. Dtsch. Dermatol. Ges. 10, S1–S31 (2012).
pubmed: 23110516
doi: 10.1111/j.1610-0387.2012.08006.x
pmcid: 23110516
Zouboulis, C. C. et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J. Eur. Acad. Dermatol. Venereol. 29, 619–644 (2015).
pubmed: 25640693
doi: 10.1111/jdv.12966
pmcid: 25640693
Sabat, R. et al. Acne inversa/hidradenitis suppurativa: an update. Hautarzt 68, 999–1006 (2017).
pubmed: 29159469
doi: 10.1007/s00105-017-4082-5
pmcid: 29159469
Dauden, E. et al. Recommendations for the management of comorbidity in hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 32, 129–144 (2018).
pubmed: 28796920
doi: 10.1111/jdv.14517
pmcid: 28796920
Nielsen, R. M., Lindso Andersen, P., Sigsgaard, V., Theut Riis, P. & Jemec, G. B. Pain perception in patients with hidradenitis suppurativa. Br. J. Dermatol. 182, 166–174 (2019).
pubmed: 30919930
pmcid: 30919930
WHO. Scoping document for WHO guidelines for the pharmacological treatment of persisting pain in adults with medical illnesses. https://www.who.int/medicines/areas/quality_safety/Scoping_WHO_GLs_PersistPainAdults_webversion.pdf?ua=1 (2012).
Clemmensen, O. J. Topical treatment of hidradenitis suppurativa with clindamycin. Int. J. Dermatol. 22, 325–328 (1983).
pubmed: 6347922
doi: 10.1111/j.1365-4362.1983.tb02150.x
pmcid: 6347922
Fischer, A. H., Haskin, A. & Okoye, G. A. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J. Am. Acad. Dermatol. 76, 309–313 (2017).
pubmed: 27742173
doi: 10.1016/j.jaad.2016.08.001
pmcid: 27742173
Jemec, G. B. & Wendelboe, P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J. Am. Acad. Dermatol. 39, 971–974 (1998).
pubmed: 9843011
doi: 10.1016/S0190-9622(98)70272-5
pmcid: 9843011
Matusiak, L., Bieniek, A. & Szepietowski, J. C. Bacteriology of hidradenitis suppurativa — which antibiotics are the treatment of choice? Acta Derm. Venereol. 94, 699–702 (2014).
pubmed: 24604152
doi: 10.2340/00015555-1841
pmcid: 24604152
Scheinfeld, N. Hidradenitis suppurativa: a practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol. Online J. 19, 1 (2013).
pubmed: 24021361
pmcid: 24021361
Mendonca, C. O. & Griffiths, C. E. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br. J. Dermatol. 154, 977–978 (2006).
pubmed: 16634904
doi: 10.1111/j.1365-2133.2006.07155.x
pmcid: 16634904
Bettoli, V., Join-Lambert, O. & Nassif, A. Antibiotic treatment of hidradenitis suppurativa. Dermatol. Clin. 34, 81–89 (2016).
pubmed: 26617361
doi: 10.1016/j.det.2015.08.013
pmcid: 26617361
Join-Lambert, O. et al. Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination. Eur. J. Dermatol. 24, 94–95 (2014).
pubmed: 24445967
doi: 10.1684/ejd.2013.2213
pmcid: 24445967
Albrecht, J., Baine, P. A., Ladizinski, B., Jemec, G. B. & Bigby, M. Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A critically appraised topic. Br. J. Dermatol. 180, 749–755 (2019).
pubmed: 30281779
doi: 10.1111/bjd.17265
pmcid: 30281779
Join-Lambert, O. et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J. Antimicrob. Chemother. 71, 513–520 (2016).
pubmed: 26565016
doi: 10.1093/jac/dkv361
pmcid: 26565016
Join-Lambert, O. et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology 222, 49–58 (2011).
pubmed: 21109728
doi: 10.1159/000321716
pmcid: 21109728
Yazdanyar, S., Boer, J., Ingvarsson, G., Szepietowski, J. C. & Jemec, G. B. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology 222, 342–346 (2011).
pubmed: 21757878
doi: 10.1159/000329023
pmcid: 21757878
Riis, P. T. et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J. Am. Acad. Dermatol. 75, 1151–1155 (2016).
pubmed: 27692735
doi: 10.1016/j.jaad.2016.06.049
pmcid: 27692735
Kimball, A. B. et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J. Eur. Acad. Dermatol. Venereol. 30, 989–994 (2016).
pubmed: 26201313
doi: 10.1111/jdv.13216
pmcid: 26201313
Kimball, A. B., Ganguli, A. & Fleischer, A. Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 32, 2254–2256 (2018).
pubmed: 29959796
doi: 10.1111/jdv.15163
pmcid: 29959796
Zouboulis, C. C. et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J. Am. Acad. Dermatol. 80, 60–69 e62 (2019).
pubmed: 29860040
doi: 10.1016/j.jaad.2018.05.040
pmcid: 29860040
Tzanetakou, V. et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 152, 52–59 (2016).
pubmed: 26579854
doi: 10.1001/jamadermatol.2015.3903
pmcid: 26579854
Maarouf, M., Clark, A. K., Lee, D. E. & Shi, V. Y. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J. Dermatol. Treat. 29, 441–449 (2018).
doi: 10.1080/09546634.2017.1395806
Kanni, T. et al. MABp1 targeting IL-1α for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study. J. Invest. Dermatol. 138, 795–801 (2018).
pubmed: 29129600
doi: 10.1016/j.jid.2017.10.030
pmcid: 29129600
Weber, P., Seyed Jafari, S. M., Yawalkar, N. & Hunger, R. E. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients. J. Am. Acad. Dermatol. 76, 1189–1191 (2017).
pubmed: 28522043
doi: 10.1016/j.jaad.2017.02.026
pmcid: 28522043
Kerdel, F. R. et al. Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study. J. Drugs Dermatol. 18, 170–176 (2019).
pubmed: 30811140
pmcid: 30811140
Vossen, A., van Doorn, M. B. A., van der Zee, H. H. & Prens, E. P. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J. Am. Acad. Dermatol. 80, 80–88 (2019).
pubmed: 30482392
doi: 10.1016/j.jaad.2018.06.046
pmcid: 30482392
van der Zee, H. H., Prens, E. P. & Boer, J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J. Am. Acad. Dermatol. 63, 475–480 (2010). This paper introduces a practical surgical technique of great clinical use in the management of HS.
pubmed: 20708472
doi: 10.1016/j.jaad.2009.12.018
pmcid: 20708472
Lapins, J., Marcusson, J. A. & Emtestam, L. Surgical treatment of chronic hidradenitis suppurativa: CO2 laser stripping-secondary intention technique. Br. J. Dermatol. 131, 551–556 (1994). This paper gives detailed insight into a useful management technique for HS of intermediate severity.
pubmed: 7947209
doi: 10.1111/j.1365-2133.1994.tb08559.x
pmcid: 7947209
Blok, J. L., Spoo, J. R., Leeman, F. W., Jonkman, M. F. & Horvath, B. Skin-Tissue-sparing Excision with Electrosurgical Peeling (STEEP): a surgical treatment option for severe hidradenitis suppurativa Hurley stage II/III. J. Eur. Acad. Dermatol. Venereol. 29, 379–382 (2015).
pubmed: 24460855
doi: 10.1111/jdv.12376
pmcid: 24460855
Janse, I., Bieniek, A., Horvath, B. & Matusiak, L. Surgical procedures in hidradenitis suppurativa. Dermatol. Clin. 34, 97–109 (2016).
pubmed: 26617363
doi: 10.1016/j.det.2015.08.007
pmcid: 26617363
Morgan, W. P., Harding, K. G. & Hughes, L. E. A comparison of skin grafting and healing by granulation, following axillary excision for hidradenitis suppurativa. Ann. R. Coll. Surg. Engl. 65, 235–236 (1983).
pubmed: 6347013
pmcid: 2494302
Tierney, E., Mahmoud, B. H., Hexsel, C., Ozog, D. & Hamzavi, I. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol. Surg. 35, 1188–1198 (2009). This paper describes the utility of Nd:YAG treatment in HS.
pubmed: 19438670
doi: 10.1111/j.1524-4725.2009.01214.x
pmcid: 19438670
Saunte, D. M. & Lapins, J. Lasers and intense pulsed light hidradenitis suppurativa. Dermatol. Clin. 34, 111–119 (2016).
pubmed: 26617364
doi: 10.1016/j.det.2015.08.001
pmcid: 26617364
Matusiak, L., Bieniek, A. & Szepietowski, J. C. Psychophysical aspects of hidradenitis suppurativa. Acta Derm. Venereol. 90, 264–268 (2010).
pubmed: 20526543
doi: 10.2340/00015555-0866
pmcid: 20526543
von der Werth, J. M. & Jemec, G. B. Morbidity in patients with hidradenitis suppurativa. Br. J. Dermatol. 144, 809–813 (2001). This paper describes a cross-sectional study that broadly demonstrates the health-related quality of life measures and elucidates key factors that make HS more burdensome, emphasizing the important role of health care providers in diminishing disease burden.
pubmed: 11298541
doi: 10.1046/j.1365-2133.2001.04137.x
pmcid: 11298541
Onderdijk, A. J. et al. Depression in patients with hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 27, 473–478 (2013).
pubmed: 22339940
doi: 10.1111/j.1468-3083.2012.04468.x
pmcid: 22339940
Matusiak, L., Szczech, J., Kaaz, K., Lelonek, E. & Szepietowski, J. C. Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm. Venereol. 98, 191–194 (2018).
pubmed: 28971209
doi: 10.2340/00015555-2815
pmcid: 28971209
Smith, H. S., Chao, J. D. & Teitelbaum, J. Painful hidradenitis suppurativa. Clin. J. Pain. 26, 435–444 (2010).
pubmed: 20473053
doi: 10.1097/AJP.0b013e3181ceb80c
pmcid: 20473053
Wolkenstein, P. et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J. Am. Acad. Dermatol. 56, 621–623 (2007).
pubmed: 17097366
doi: 10.1016/j.jaad.2006.08.061
pmcid: 17097366
Kaaz, K., Szepietowski, J. C. & Matusiak, L. Influence of itch and pain on sleep quality in patients with hidradenitis suppurativa. Acta Derm. Venereol. 98, 757–761 (2018).
pubmed: 29756157
doi: 10.2340/00015555-2967
pmcid: 29756157
Vossen, A., Schoenmakers, A., van Straalen, K. R., Prens, E. P. & van der Zee, H. H. Assessing pruritus in hidradenitis suppurativa: a cross-sectional study. Am. J. Clin. Dermatol. 18, 687–695 (2017).
pubmed: 28429245
pmcid: 5602064
doi: 10.1007/s40257-017-0280-2
Kurek, A. et al. Profound disturbances of sexual health in patients with acne inversa. J. Am. Acad. Dermatol. 67, 422–428 (2012).
pubmed: 22182915
doi: 10.1016/j.jaad.2011.10.024
pmcid: 22182915
Sampogna, F. et al. Impairment of sexual life in 3,485 dermatological outpatients from a multicentre study in 13 European countries. Acta Derm. Venereol. 97, 478–482 (2017).
pubmed: 27819713
doi: 10.2340/00015555-2561
pmcid: 27819713
Jemec, G. B., Heidenheim, M. & Nielsen, N. H. Hidradenitis suppurativa — characteristics and consequences. Clin. Exp. Dermatol. 21, 419–423 (1996).
pubmed: 9167336
doi: 10.1111/j.1365-2230.1996.tb00145.x
pmcid: 9167336
Machado, M. O. et al. Depression and anxiety in adults with hidradenitis suppurativa: a systematic review and meta-analysis. JAMA Dermatol. https://doi.org/10.1001/jamadermatol.2019.0759 (2019).
doi: 10.1001/jamadermatol.2019.0759
pubmed: 31166590
pmcid: 31166590
Thorlacius, L., Cohen, A. D., Gislason, G. H., Jemec, G. B. E. & Egeberg, A. Increased suicide risk in patients with hidradenitis suppurativa. J. Invest. Dermatol. 138, 52–57 (2018). This paper reports on a registry-based study that clearly demonstrates the increased risk of suicide among patients with HS compared with the general population.
pubmed: 28942360
doi: 10.1016/j.jid.2017.09.008
pmcid: 28942360
Schneider-Burrus, S. et al. Association of hidradenitis suppurativa with body image. JAMA Dermatol. 154, 447–451 (2018).
pubmed: 29466546
pmcid: 5876839
doi: 10.1001/jamadermatol.2017.6058
Esmann, S. & Jemec, G. B. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm. Venereol. 91, 328–332 (2011).
pubmed: 21394419
doi: 10.2340/00015555-1082
pmcid: 21394419
Scala, E. et al. A new Th-17 cytokine in hidradenitis suppurativa: antimicrobial and pro-inflammatory role of IL-26. Br. J. Dermatol. https://doi.org/10.1111/bjd.17854 (2019).
doi: 10.1111/bjd.17854
pubmed: 30829398
pmcid: 30829398
Lima, A. L. et al. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br. J. Dermatol. 174, 514–521 (2016).
pubmed: 26436522
doi: 10.1111/bjd.14214
pmcid: 26436522
Witte, K. et al. Increased presence and differential molecular imprinting of transit amplifying cells in psoriasis. J. Mol. Med. 98, 111–122 (2020).
pubmed: 31832701
doi: 10.1007/s00109-019-01860-3
pmcid: 31832701
Ring, H. C. et al. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls. JAMA Dermatol. 153, 897–905 (2017).
pubmed: 28538949
pmcid: 5710430
doi: 10.1001/jamadermatol.2017.0904
Clark, A. K., Quinonez, R. L., Saric, S. & Sivamani, R. K. Hormonal therapies for hidradenitis suppurativa: review. Dermatol. Online J. 23, 13030/qt6383k0n4 (2017).
pubmed: 29469777
pmcid: 29469777
Golbari, N. M., Porter, M. L. & Kimball, A. B. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J. Am. Acad. Dermatol. 80, 114–119 (2019).
pubmed: 30003993
doi: 10.1016/j.jaad.2018.06.063
pmcid: 30003993
Loget, J. et al. Misdiagnosis of hidradenitis suppurativa continues to be a major issue. The R-ENS Verneuil study. Ann. Dermatol. Venereol. 145, 331–338 (2018).
pubmed: 29704958
doi: 10.1016/j.annder.2018.01.043
pmcid: 29704958
Canoui-Poitrine, F. et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J. Invest. Dermatol. 133, 1506–1511 (2013).
pubmed: 23235532
doi: 10.1038/jid.2012.472
pmcid: 23235532
Kimball, A. B., Sundaram, M., Banderas, B., Foley, C. & Shields, A. L. Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa. J. Dermatol. Treat. 29, 152–164 (2018).
doi: 10.1080/09546634.2017.1341614
Thorlacius, L. et al. Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. Br. J. Dermatol. 178, 715–721 (2018).
pubmed: 29080368
pmcid: 5935265
doi: 10.1111/bjd.16093
Porter, M. L., Golbari, N. M., Lockwood, S. J. & Kimball, A. B. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. Semin. Cutan. Med. Surg. 37, 182–189 (2018).
pubmed: 30215636
doi: 10.12788/j.sder.2018.042
pmcid: 30215636